About us

Enabling more human-relevant, predictive & reproducible assays

We think physiological conditions shouldn't compromise scalability of your model. So we build a dynamic cell culture platform that fits in your current standard workflows.

Founded
2024Spun out of TU Eindhoven
Now validating
First24WellsThe first MACplate format
In the developmental pipeline
96WellsHigher-throughput format
Team
8Core team members, besides key opinion leader advisors
About us

Mission & vision

Mission

Enabling scientists to create more predictive human-relevant models without additional complexity, by make controlled dynamic conditions broadly accessible within standard cell-culture systems

Vision

A future in which human-relevant in-vitro models play a central role in preclinical drug development, reducing dependence on animal testing and supporting more effective and sustainable drug development

Trusted by

(Pilot) customers

02
  • Erasmus MC
  • University of Galway

Partners / Backed by

14
  • Eindhoven University of Technology
  • Brabantse Ontwikkelings Maatschappij
  • Brabant Startup Fonds
  • Rabobank
  • NWO
  • Co-funded by the European Union
  • Health~Holland
  • MIT Zuid
  • Metropoolregio Eindhoven
  • 4TU Startups
  • DayOne
  • The Gate — Brainport Eindhoven
  • TTT MedTech
  • Venture Challenge
  • Eindhoven University of Technology
  • Brabantse Ontwikkelings Maatschappij
  • Brabant Startup Fonds
  • Rabobank
  • NWO
  • Co-funded by the European Union
  • Health~Holland
  • MIT Zuid
  • Metropoolregio Eindhoven
  • 4TU Startups
  • DayOne
  • The Gate — Brainport Eindhoven
  • TTT MedTech
  • Venture Challenge
Our story

From cilia research to a more predictive assay

  1. Research origin · 2012

    Magnetic artificial cilia research at Eindhoven University of Technology showed that nature-inspired micro-actuators can move liquid without requiring an external pump.

  2. Founding · 2024

    ARTIC was founded to turn that scientific principle into a product with societal impact.

  3. Customer need · 2024–2025

    Unmet need discovery, early customer validation.

  4. Today

    First pilots, biological proof of concept for gut permeability, laying the foundation for prototype into product development.

Roadmap

Where we are heading

Now
  • FlowGUT Proof of concept: Permeability prediction for low-permeable reference drugs: MACplate vs static
  • MACplate 24 in development and early tests with gut permeability customers
Next
  • MACplate 96 in the development pipeline
  • FlowIMMUNE application
Careers

Open roles

We are not advertising vacancies right now, but if you work on Microphysiological systems, cell culture or a related application area, we still want to hear from you.

Send an open application

Work with us

Pilots, partnerships, investment or a role on the team. Start with a chat

Get in touch